Bissery MC - Search Results

1

Preclinical evaluation of docetaxel (Taxotere).

Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P, André S. Lavelle F, et al. Among authors: bissery mc. Semin Oncol. 1995 Apr;22(2 Suppl 4):3-16. Semin Oncol. 1995. PMID: 7740328 Review.

2

Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.

Vrignaud P, Sémiond D, Lejeune P, Bouchard H, Calvet L, Combeau C, Riou JF, Commerçon A, Lavelle F, Bissery MC. Vrignaud P, et al. Among authors: bissery mc. Clin Cancer Res. 2013 Jun 1;19(11):2973-83. doi: 10.1158/1078-0432.CCR-12-3146. Epub 2013 Apr 15. Clin Cancer Res. 2013. PMID: 23589177

3

Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.

Bissery MC, Guénard D, Guéritte-Voegelein F, Lavelle F. Bissery MC, et al. Cancer Res. 1991 Sep 15;51(18):4845-52. Cancer Res. 1991. PMID: 1680023

4

Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience.

Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Bissery MC, et al. Anticancer Drugs. 1995 Jun;6(3):339-55, 363-8. doi: 10.1097/00001813-199506000-00001. Anticancer Drugs. 1995. PMID: 7670132 Review.

5

Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination.

Bissery MC, Vrignaud P, Lavelle F. Bissery MC, et al. Semin Oncol. 1995 Dec;22(6 Suppl 13):3-16. Semin Oncol. 1995. PMID: 8604451

6

Preclinical evaluation of CPT-11 and its active metabolite SN-38.

Lavelle F, Bissery MC, André S, Roquet F, Riou JF. Lavelle F, et al. Among authors: bissery mc. Semin Oncol. 1996 Feb;23(1 Suppl 3):11-20. Semin Oncol. 1996. PMID: 8633248 Review.

7

Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.

Bissery MC, Vrignaud P, Lavelle F, Chabot GG. Bissery MC, et al. Anticancer Drugs. 1996 Jun;7(4):437-60. doi: 10.1097/00001813-199606000-00010. Anticancer Drugs. 1996. PMID: 8826613

8

Preclinical antitumor activity and pharmacokinetics of irinotecan (CPT-11) in tumor-bearing mice.

Bissery MC, Vrignaud P, Lavelle F, Chabot GG. Bissery MC, et al. Ann N Y Acad Sci. 1996 Dec 13;803:173-80. doi: 10.1111/j.1749-6632.1996.tb26386.x. Ann N Y Acad Sci. 1996. PMID: 8993510 Review. No abstract available.

9

Synthesis and biological evaluation of amino-substituted benzo[f]pyrido[4,3-b] and pyrido[3,4-b]quinoxalines: a new class of antineoplastic agents.

Nguyen CH, Fan E, Riou JF, Bissery MC, Vrignaud P, Lavelle F, Bisagni E. Nguyen CH, et al. Among authors: bissery mc. Anticancer Drug Des. 1995 Jun;10(4):277-97. Anticancer Drug Des. 1995. PMID: 7786395

10

Synthesis and structure-activity relationships of new antitumor taxoids. Effects of cyclohexyl substitution at the C-3' and/or C-2 of taxotere (docetaxel).

Ojima I, Duclos O, Zucco M, Bissery MC, Combeau C, Vrignaud P, Riou JF, Lavelle F. Ojima I, et al. Among authors: bissery mc. J Med Chem. 1994 Aug 5;37(16):2602-8. doi: 10.1021/jm00042a013. J Med Chem. 1994. PMID: 7914541

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

62 results

Search Page

Filters